411 related articles for article (PubMed ID: 19485912)
1. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT).
Zarrabeitia R; Albiñana V; Salcedo M; Señaris-Gonzalez B; Fernandez-Forcelledo JL; Botella LM
Curr Vasc Pharmacol; 2010 Jul; 8(4):473-81. PubMed ID: 19485912
[TBL] [Abstract][Full Text] [Related]
2. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century.
Begbie ME; Wallace GM; Shovlin CL
Postgrad Med J; 2003 Jan; 79(927):18-24. PubMed ID: 12566546
[TBL] [Abstract][Full Text] [Related]
3. How to manage patients with hereditary haemorrhagic telangiectasia.
Geisthoff UW; Nguyen HL; Röth A; Seyfert U
Br J Haematol; 2015 Nov; 171(4):443-52. PubMed ID: 26205234
[TBL] [Abstract][Full Text] [Related]
4. Understanding hereditary hemorrhagic telangiectasia: From genetic anomalies to systemic manifestations, quality of life, and epistaxis management-Exploring the otolaryngologist's integral role.
Hayama M; Maeda Y; Obata S; Tsuda T; Takeda K; Nishida T; Inohara H
Auris Nasus Larynx; 2024 Apr; 51(2):305-312. PubMed ID: 38008660
[TBL] [Abstract][Full Text] [Related]
5. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.
Harrison L; Kundra A; Jervis P
J Laryngol Otol; 2018 Oct; 132(10):866-871. PubMed ID: 30191780
[TBL] [Abstract][Full Text] [Related]
6. Local sclerotherapy with polydocanol (Aethoxysklerol®) for the treatment of Epistaxis in Rendu-Osler-Weber or Hereditary Hemorrhagic Telangiectasia (HHT): 15 years of experience.
Morais D; Millás T; Zarrabeitia R; Botella LM; Almaraz A
Rhinology; 2012 Mar; 50(1):80-6. PubMed ID: 22469609
[TBL] [Abstract][Full Text] [Related]
7. Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding.
Beckman JD; Li Q; Hester ST; Leitner O; Smith KL; Kasthuri RS
Orphanet J Rare Dis; 2020 Jul; 15(1):185. PubMed ID: 32660636
[TBL] [Abstract][Full Text] [Related]
8. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.
Albiñana V; Bernabeu-Herrero ME; Zarrabeitia R; Bernabéu C; Botella LM
Thromb Haemost; 2010 Mar; 103(3):525-34. PubMed ID: 20135064
[TBL] [Abstract][Full Text] [Related]
9. Laser-Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.
Abiri A; Goshtasbi K; Maducdoc M; Sahyouni R; Wang MB; Kuan EC
Lasers Surg Med; 2020 Apr; 52(4):293-300. PubMed ID: 31441079
[TBL] [Abstract][Full Text] [Related]
10. Medical management of haemorrhagic hereditary telangiectasia in adult patients.
Riera-Mestre A; Ribas J; Castellote J
Med Clin (Barc); 2019 Apr; 152(7):274-280. PubMed ID: 30502301
[TBL] [Abstract][Full Text] [Related]
11. Rendu-Osler-Weber disease: experience with 56 patients.
Sabbà C; Pasculli G; Cirulli A; Gallitelli M; Virgilio G; Guastamacchia E; Resta F; Palasciano G
Ann Ital Med Int; 2002; 17(3):173-9. PubMed ID: 12402665
[TBL] [Abstract][Full Text] [Related]
12. Hereditary hemorrhagic telangiectasia. Genetics, pathogenesis, clinical manifestation and management.
Stuhrmann M; El-Harith el-HA
Saudi Med J; 2007 Jan; 28(1):11-21. PubMed ID: 17206283
[TBL] [Abstract][Full Text] [Related]
13. Osler-Weber-Rendu Syndrome in Relation to Dermatology.
Orizaga-Y-Quiroga TL; Villarreal-Martínez A; Jaramillo-Moreno G; Ocampo-Candiani J
Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):526-532. PubMed ID: 30975431
[TBL] [Abstract][Full Text] [Related]
14. Complications from office sclerotherapy for epistaxis due to hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu).
Hanks JE; Hunter D; Goding GS; Boyer HC
Int Forum Allergy Rhinol; 2014 May; 4(5):422-7. PubMed ID: 24431220
[TBL] [Abstract][Full Text] [Related]
15. Epistaxis in hereditary haemorrhagic telangiectasia.
Haitjema T; Balder W; Disch FJ; Westermann CJ
Rhinology; 1996 Sep; 34(3):176-8. PubMed ID: 8938889
[TBL] [Abstract][Full Text] [Related]
16. [Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): clinical manifestations and multidisciplinary management].
Frigerio C; Aebischer N; Baud D; Bonafe L; Fellmanne F; Ikonomidis C; Mazzolai L; Michel P; Nichita C; Qanadli SD; Lazor R
Rev Med Suisse; 2016 May; 12(517):896-901. PubMed ID: 27323484
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease).
Cottin V; Dupuis-Girod S; Lesca G; Cordier JF
Respiration; 2007; 74(4):361-78. PubMed ID: 17641482
[TBL] [Abstract][Full Text] [Related]
18. Hereditary haemorrhagic telangiectasia.
Sharathkumar AA; Shapiro A
Haemophilia; 2008 Nov; 14(6):1269-80. PubMed ID: 19141168
[TBL] [Abstract][Full Text] [Related]
19. TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT) - Study protocol of the prospective, randomized, double-blind, controlled cross-over TIM-HHT trial.
Andorfer KEC; Seebauer CT; Koller M; Zeman F; Berneburg M; Fischer R; Vielsmeier V; Bohr C; Kühnel TS
Clin Hemorheol Microcirc; 2022; 80(3):307-315. PubMed ID: 34864649
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
